GlassScriptPhysician profile
Anna D Harp
NPI 1235844168
$3,385.33
in general payments reported to CMS, 2019-2025
30 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $200 · 2024: $1,017 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,385.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.26 | 2023-2025 | |
| Madrigal Pharmaceuticals | $339.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $288.47 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.10 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $176.24 | 2023-2025 | Tagrisso, Andexxa, Fasenra |
| Lilly USA, LLC | $158.78 | 2024-2025 | Omvoh, Zepbound |
| Grifols USA, LLC | $150.35 | 2024-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $136.50 | 2023-2025 | Dupixent |
| Genzyme Corporation | $131.42 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $113.45 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $112.45 | 2024-2025 | Entyvio, Hyqvia |
| Echosens North America, INC. | $85.49 | 2024 | Fibroscan |
| Ardelyx, INC. | $82.56 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $65.35 | 2025 | Suflave |
| Harmony Biosciences LLC | $52.01 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $47.49 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $43.96 | 2024 | |
| Merck Sharp & Dohme LLC | $39.44 | 2025 | Zerbaxa |
| Teva Pharmaceuticals USA, INC. | $34.75 | 2023-2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.26 | 2025 | Ofev |
| Ucb, INC. | $26.63 | 2024 | Rystiggo |
| Ipsen Biopharmaceuticals, INC | $24.30 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $21.51 | 2023 | Gimoti |
| Amneal Pharmaceuticals LLC | $21.41 | 2024 | Rytary |
| Novo Nordisk INC | $18.62 | 2025 | Wegovy |
| Gilead Sciences, INC. | $18.51 | 2025 | |
| Genmab U.S., INC. | $18.41 | 2024 | Tivdak |
| Baxter Healthcare | $18.09 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Olympus America INC. | $17.61 | 2024 | Evis Exera III Colonovideoscope |
| Pfizer INC. | $16.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.